CL2023002099A1 - Moléculas de unión al antígeno multiespecíficas dirigidas a claudina-6 y sus usos - Google Patents

Moléculas de unión al antígeno multiespecíficas dirigidas a claudina-6 y sus usos

Info

Publication number
CL2023002099A1
CL2023002099A1 CL2023002099A CL2023002099A CL2023002099A1 CL 2023002099 A1 CL2023002099 A1 CL 2023002099A1 CL 2023002099 A CL2023002099 A CL 2023002099A CL 2023002099 A CL2023002099 A CL 2023002099A CL 2023002099 A1 CL2023002099 A1 CL 2023002099A1
Authority
CL
Chile
Prior art keywords
cldn6
multispecific antigen
binding molecules
binding
molecules targeting
Prior art date
Application number
CL2023002099A
Other languages
English (en)
Inventor
Ishii Shinya
Kimura Naoki
Kodama Tatsushi
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CL2023002099A1 publication Critical patent/CL2023002099A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Environmental Sciences (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención proporciona moléculas multiespecíficas de unión a antígeno capaces de unirse a CD3 y CD137 (4-1BB) pero no de unirse a CD3 y CD137 al mismo tiempo, y capaces de unirse a CLDN6. Las moléculas de unión a antígeno multiespecíficas de la presente divulgación exhiben una actividad de citotoxicidad dependiente de células T mejorada de una manera dependiente de CLDN6 mediante la unión a CD3/CD37 y CLDN6. La presente invención proporciona las moléculas de unión al antígeno multiespecíficas y las composiciones farmacéuticas de estas se pueden usar para dirigirse a células que expresan CLDN6, para usar en inmunoterapia para tratar varios cánceres, especialmente aquellos asociados con CLDN6 tales como cánceres positivos para CLDN6.
CL2023002099A 2020-03-31 2023-07-19 Moléculas de unión al antígeno multiespecíficas dirigidas a claudina-6 y sus usos CL2023002099A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020062881 2020-03-31
JP2020073335 2020-04-16

Publications (1)

Publication Number Publication Date
CL2023002099A1 true CL2023002099A1 (es) 2023-12-22

Family

ID=77928433

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2022002625A CL2022002625A1 (es) 2020-03-31 2022-09-27 Moléculas de unión al antígeno multiespecíficas dirigidas a claudina-6 y sus usos
CL2023002099A CL2023002099A1 (es) 2020-03-31 2023-07-19 Moléculas de unión al antígeno multiespecíficas dirigidas a claudina-6 y sus usos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2022002625A CL2022002625A1 (es) 2020-03-31 2022-09-27 Moléculas de unión al antígeno multiespecíficas dirigidas a claudina-6 y sus usos

Country Status (17)

Country Link
US (1) US20230220066A1 (es)
EP (1) EP4126956A4 (es)
JP (2) JP6971419B2 (es)
KR (2) KR20220149774A (es)
CN (1) CN115397855A (es)
AU (1) AU2021247916A1 (es)
BR (1) BR112022017305A2 (es)
CA (1) CA3174094A1 (es)
CL (2) CL2022002625A1 (es)
CO (1) CO2022015202A2 (es)
CR (1) CR20220540A (es)
IL (1) IL296478A (es)
MX (1) MX2022012092A (es)
PE (1) PE20221760A1 (es)
SG (1) SG11202104264TA (es)
TW (2) TW202235442A (es)
WO (1) WO2021200939A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113278076A (zh) 2013-11-11 2021-08-20 中外制药株式会社 含有改变了抗体可变区的抗原结合分子
JP7357616B2 (ja) 2017-12-05 2023-10-06 中外製薬株式会社 Ｃｄ３およびｃｄ１３７に結合する改変された抗体可変領域を含む抗原結合分子
JPWO2023053282A1 (es) * 2021-09-29 2023-04-06
WO2023131329A1 (en) * 2022-01-09 2023-07-13 I-Mab Biopharma Co., Ltd. Multispecific constructs and uses thereof
WO2024085166A1 (ja) * 2022-10-19 2024-04-25 アステラス製薬株式会社 がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2241578B1 (en) 2008-01-11 2016-04-20 The University of Tokyo Anti-cldn6 antibody
BR112012011143B1 (pt) 2009-11-11 2020-05-19 Ganymed Pharmaceuticals Ag "anticorpos específicos para claudina 6 (cldn6)".
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
MX341147B (es) 2011-05-13 2016-08-09 Ganymed Pharmaceuticals Ag Anticuerpos para el tratamiento del cáncer que expresa cldn6.
WO2014075697A1 (en) 2012-11-13 2014-05-22 Biontech Ag Agents for treatment of claudin expressing cancer diseases
AU2013347184B2 (en) 2012-11-13 2018-06-14 Astellas Pharma Inc. Agents for treatment of claudin expressing cancer diseases
PE20160870A1 (es) 2013-11-06 2016-09-09 Abbvie Stemcentrx Llc Anticuerpos anti-claudina novedosos y metodos de uso
WO2018054484A1 (en) * 2016-09-23 2018-03-29 Biontech Ag Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
JP7357616B2 (ja) * 2017-12-05 2023-10-06 中外製薬株式会社 Ｃｄ３およびｃｄ１３７に結合する改変された抗体可変領域を含む抗原結合分子
WO2019135404A1 (en) * 2018-01-05 2019-07-11 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent
BR112021005472A2 (pt) * 2018-09-28 2021-06-15 Chugai Seiyaku Kabushiki Kaisha molécula de ligação ao antígeno compreendendo uma região variável do anticorpo alterada
CN113950485A (zh) * 2019-07-10 2022-01-18 中外制药株式会社 密蛋白-6结合分子及其用途

Also Published As

Publication number Publication date
KR20210143923A (ko) 2021-11-29
WO2021200939A1 (en) 2021-10-07
CO2022015202A2 (es) 2022-11-18
SG11202104264TA (en) 2021-11-29
EP4126956A1 (en) 2023-02-08
KR102431028B1 (ko) 2022-08-10
AU2021247916A1 (en) 2022-10-20
CA3174094A1 (en) 2021-10-07
JP2022009816A (ja) 2022-01-14
US20230220066A1 (en) 2023-07-13
CN115397855A (zh) 2022-11-25
TW202204408A (zh) 2022-02-01
KR20220149774A (ko) 2022-11-08
PE20221760A1 (es) 2022-11-11
CL2022002625A1 (es) 2023-04-21
CR20220540A (es) 2022-12-07
JP2021168648A (ja) 2021-10-28
EP4126956A4 (en) 2024-04-24
MX2022012092A (es) 2022-10-13
TW202235442A (zh) 2022-09-16
TWI770917B (zh) 2022-07-11
IL296478A (en) 2022-11-01
BR112022017305A2 (pt) 2022-10-11
JP6971419B2 (ja) 2021-11-24

Similar Documents

Publication Publication Date Title
CL2023002099A1 (es) Moléculas de unión al antígeno multiespecíficas dirigidas a claudina-6 y sus usos
CU20200089A7 (es) Moléculas de unión contra bcma
AR114031A2 (es) Moléculas de unión a 4-1bb
CL2020003028A1 (es) Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos.
BR112017014551A2 (pt) ?anticorpo, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos para tratamento de uma doença, para produção de um anticorpo biespecífico e para detecção da possível ocorrência de reticulação entre células com expressão de cd3 e cd20 em uma amostra derivada de um paciente, uso de um anticorpo biespecífico, e, kit?
ECSP20018586A (es) Compuestos que contienen pirazolopirimidinona y sus usos
MX2020003856A (es) Proteinas de union a antigenos de maduracion de celulas b.
CL2023002108A1 (es) Proteínas unión multiespecíficas se unen a cd33, nkg2d, cd16, métodos de uso.
BR112018005573A2 (pt) ?polipeptídeos de ligação a cd3?
CL2022000664A1 (es) Proteínas de fijación multiespecíficas para tratamiento contra el cáncer
CL2018000750A1 (es) Método de redireccionamiento de linfocitos t para el tratamiento de la infección por vih
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
PH12019501387A1 (en) Anti-cd3 antibody and molecules comprising the antibody
AR121695A1 (es) Moléculas de unión al antígeno multiespecíficas dirigidas a dll3 y sus usos
EP4249064A3 (en) Novel fusion protein specific for cd137 and pd-l1
EA202092202A1 (ru) Конструкции антител к ror
CO2019009815A2 (es) Combinaciones farmacéuticas
EA201890572A1 (ru) Биофармацевтические композиции
AR119746A1 (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
CL2021000849A1 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos (divisional de la solicitud no. 201900999)
BR112022003740A2 (pt) Anticorpos anti-cd96 e métodos de uso dos mesmos
MX2018014554A (es) Anticuerpo penetrante de citosol y uso del mismo.
BR112017016379A2 (pt) imunoconjugados, composição, uso de peptídeo, uso de imunoconjugado, método de geração de imunoconjugado e método de tratamento de pacientes
CL2022000096A1 (es) Anticuerpos anti-tigit y aplicación de los mismos
AR117950A1 (es) Receptores quiméricos de steap1 y composición farmacéutica que los contienen